Effect of perioperative randiolol administration on inhibiting postoperative Atrial Fibrillation.

Effect of perioperative randiolol administration on inhibiting postoperative Atrial Fibrillation. - IDEAL study

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000008472

Enrollment

Registered

2012-07-20

Start date

2012-07-20

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with preoperative EFs 40% or less who undergo cardiovascular operations using cariopulmonary bypass machine or Off Pump CABG (OPCAB) in the Department of Cardiovascular Surgery, Osaka University Hospital.

Interventions

administration of landiolol

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients without preoperative chronic atrial fibrillation.

Exclusion criteria

Exclusion criteria: 1. Patients with cardiogenic shock 2. Patients with diabetic ketoacidosis and metabolic acidosis 3. Patients with bradycardia such as atrioventricular block (II degree or higher) and sick sinus syndrome 4. Patients with right heart failure due to pulmonary hypertension 5. Patients with congestive heart failure 6. Patients with untreated pheochromocytoma 7. Patients with a past history of hypersensitivity to landiolol 8. Patients with congenital heart diseases 9. Patients undergoing heart transplantation 10. Patients with ventricular assisted devices 11. Patients with ECMO 12. Patients having atrial fibrillation immediately before administration of landiolol

Design outcomes

Primary

Measure	Time frame
occurrence of postopeartive atrial fibrillation	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026